Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Lenacapavir
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Gilead Sciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Gilead Partners with Six Generic Makers to Expand HIV Prevention Access Globally
Details : The agreement aims to make and sell generic lenacapavir, subject to required regulatory approvals, in 120 high-incidence, resource-limited countries for HIV prevention.
Product Name : Sunlenca
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 10, 2024
Lead Product(s) : Lenacapavir
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Gilead Sciences
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Clopidogrel
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Center for Bioequivalence Studies and Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 11, 2022
Lead Product(s) : Clopidogrel
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Center for Bioequivalence Studies and Clinical Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nicorandil
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Study to Assess Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment of Chronic Stable Angina.
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 20, 2011
Lead Product(s) : Nicorandil
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
